Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Roivant Sciences Q2 2026 Results: Net Loss of $192M, Loss Widens

Roivant Sciences Ltd. reported 724,561,460 common shares outstanding as of November 3, 2026. The filing includes condensed consolidated financial statements for the three and six months ended September 30, 2026, and highlights risks related to biopharmaceutical product development, capital allocation, and its 'Vant' structure.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue35.11.6
Profit before tax-166.3-159.0
Net income-191.6-113.5
EPS (diluted, $ a share)$-0.27$-0.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+2135.6%
Source

10-Q filed with the SEC, NASDAQ: ROIV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Roivant Sciences Ltd.: key numbers

Share price
$38.61Close, Nov 16
Market cap
$28B
Shares outstanding
724.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Roivant Sciences Ltd.

All →
7:01 PM ET Form 4
Insider Selling

Roivant Sciences CFO Richard Pulik Sells $12.5M of Stock

Richard Pulik, CFO, sold 300,000 shares of Roivant Sciences Ltd. at $41.20 to $42.03 a share (average $41.58) in 4 transactions, worth $12.5M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 222,046 (-17.7%).

Value
$12.5M
Shares
300,000
Average price
$41.58
Role
CFO
Holding change
-17.7%
Trade date
Nov 10, 2026 to Nov 11, 2026
7:00 PM ET Form 4
Insider Selling

Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.62M of Stock

Eric Venker, President & Immunovant CEO, sold 187,943 shares of Roivant Sciences Ltd. at $40.44 to $41.00 a share (average $40.53) in 2 transactions, worth $7.62M in total on Nov 10, 2026. Shares held after the trade: 811,211 (-3.5%).

Value
$7.62M
Shares
187,943
Average price
$40.53
Role
President & Immunovant CEO
Holding change
-3.5%
Trade date
Nov 10, 2026
7:17 AM ET 8-K
Financial Results

Roivant Sciences Financial Results

Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.

Term
Q2 2026

“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”

Matt Gline, CEO of Roivant

“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”

Matt Gline, CEO of Roivant
6:11 PM ET Form 4
Insider Selling

Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.26M of Stock

Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.31 a share, worth $7.26M in total on Nov 3, 2026. Shares held after the trade: 999,154 (-16.7%).

Value
$7.26M
Shares
200,000
Price
$36.31
Role
President & Immunovant CEO
Holding change
-16.7%
Trade date
Nov 3, 2026
6:29 PM ET Form 4
Insider Selling

Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.32M of Stock

Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.59 a share, worth $7.32M in total on Oct 28, 2026. Shares held after the trade: 1,199,154 (-14.3%).

Value
$7.32M
Shares
200,000
Price
$36.59
Role
President & Immunovant CEO
Holding change
-14.3%
Trade date
Oct 28, 2026
6:44 PM ET Form 4
Insider Selling

Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.02M of Stock

Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $35.09 to $35.42 a share (average $35.11) in 2 transactions, worth $7.02M in total on Oct 20, 2026. Shares held after the trade: 1,399,154 (-1.0%).

Value
$7.02M
Shares
200,000
Average price
$35.11
Role
President & Immunovant CEO
Holding change
-1.0%
Trade date
Oct 20, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.